Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Illumina, Inc.NASDAQ: ILMN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $134M (cash outflow) rose 2.3% year over year, ahead of the -45.7% change in trailing-twelve-month net income.

Context

  • Net income amounted to 19.6% of revenue in FY2025, down 8.4 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 14 analysts of $838.72M (-1.3%) for the fiscal year ending Dec 2026, a slowdown from the +169.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$134M-200.0% QoQ
Last fiscal yearDec 2025
$850M+169.5% YoY
LTMJun 2026
$484M-45.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%+39.3%+37.0 pp
1 year+169.5%-1.3%-170.8 pp
3-year CAGR—+8.9%—
5-year CAGR+10.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
850M USD
Year-over-year change
+169.5%
4-year CAGR
+2.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 net income of $484M is the 2nd largest of the 11 companies compared; the peer median is $100.95M.
  • Its year-over-year change of -45.7% is the 7th highest of 10, against a peer median of -11.2%.
  • Net income amounts to 10.8% of revenue for ILMN, versus a peer median of 30.7%.
ILMN Competitors Peer median
Net Income for ILMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
ILMNIllumina, Inc.LTM Jun 2026$484M -45.7%—10.8%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
NTRANatera, Inc.LTM Jun 2026$192.35M -24.0%-27.6%7.1%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$128.58M -80.5%+20.2%80.3%
WGSGeneDx Holdings Corp.LTM Jun 2026$106.36M -7664.5%-66.3%23.4%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$80.17M +23.8%-3.4%98.8%
TXG10x Genomics, Inc.LTM Jun 2026$75.13M -11.2%-36.0%12.2%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
BLLNBillionToOne, Inc.LTM Jun 2026$37.71M ——9.5%
Peer median (excluding ILMN) $100.95M-11.2%-10.5%30.7%

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income762M(4.4B)(1.16B)(1.22B)850M
Depreciation & Amortization251M394M432M354M270M
Deferred Income Tax(76M)(23M)(33M)(112M)119M
Stock-Based Compensation754M366M380M370M275M
Change in Working Capital(152M)204M(90M)(483M)(153M)
Accounts Receivables(164M)(12M)(40M)(25M)(108M)
Inventory(58M)(135M)(20M)19M(17M)
Accounts Payables60M(38M)(44M)(4M)2M
Other Working Capital10M389M14M(473M)(30M)
Other Non-Cash Items(994M)3.86B950M1.93B(282M)
Operating Cash Flow545M392M478M837M1.08B
Capital Expenditures(208M)(286M)(195M)(128M)(148M)
Acquisitions (Net)(2.44B)(265M)(29M)2M(10M)
Purchases of Investments(77M)(40M)(6M)(52M)0
Sales of Investments1.66B0000
Other Investing Activities00(1M)0103M
Investing Cash Flow(1.07B)(591M)(231M)(178M)(55M)
Debt Repayment471M991M(1.24B)491M(5M)
Common Stock Issued60M63M67M56M44M
Common Stock Repurchased000(116M)(742M)
Dividends Paid00000
Other Financing Activities(582M)(54M)(42M)(1B)(41M)
Financing Cash Flow(51M)1B(1.21B)(570M)(744M)
Effect of Forex Changes(3M)(22M)0(10M)11M
Net Change in Cash(578M)779M(963M)79M291M
Free Cash Flow337M106M282M709M931M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.